Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
Authors
Keywords
-
Journal
SCIENCE
Volume -, Issue -, Pages -
Publisher
American Association for the Advancement of Science (AAAS)
Online
2022-07-19
DOI
10.1126/science.abq0203
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
- (2022) Alexandra C. Walls et al. CELL
- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
- (2022) Wilfredo F. Garcia-Beltran et al. CELL
- SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron
- (2022) Alison Tarke et al. CELL
- SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
- (2022) Wanwisa Dejnirattisai et al. CELL
- Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
- (2022) Emma K. Accorsi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity
- (2022) Bo Meng et al. NATURE
- Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
- (2022) Elisabetta Cameroni et al. NATURE
- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
- (2022) Sandile Cele et al. NATURE
- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
- (2022) Raquel Viana et al. NATURE
- Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
- (2022) Rigel Suzuki et al. NATURE
- Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron
- (2022) Jinyan Liu et al. NATURE
- Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
- (2022) Eddy Pérez-Then et al. NATURE MEDICINE
- Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
- (2022) Peter B. Gilbert et al. SCIENCE
- Extended interval BNT162b2 vaccination enhances peak antibody generation
- (2022) Helen Parry et al. npj Vaccines
- Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine
- (2022) Rishi R. Goel et al. CELL
- mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
- (2022) Matthew Gagne et al. CELL
- Humoral and cellular immune memory to four COVID-19 vaccines
- (2022) Zeli Zhang et al. CELL
- Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
- (2022) Daichi Yamasoba et al. CELL
- SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
- (2022) Simone I. Richardson et al. Cell Host & Microbe
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
- (2022) Nick Andrews et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection
- (2022) Annika Rössler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
- (2022) Matthew McCallum et al. SCIENCE
- Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant
- (2022) Ai-ris Y. Collier et al. Science Translational Medicine
- Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model
- (2022) Stephanie N. Langel et al. Science Translational Medicine
- Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution
- (2022) Tyler N. Starr et al. SCIENCE
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- (2021) Merryn Voysey et al. LANCET
- Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
- (2021) Dami A. Collier et al. NATURE
- Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein
- (2021) Houriiyah Tegally et al. NATURE
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
- (2021) Kai Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
- (2021) Prabhu S. Arunachalam et al. NATURE
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
- (2021) Leonidas Stamatatos et al. SCIENCE
- Tackling COVID-19 with neutralizing monoclonal antibodies
- (2021) Davide Corti et al. CELL
- Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
- (2021) Alexandra C. Walls et al. CELL
- Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
- (2021) Florian A. Lempp et al. NATURE
- Spread of a SARS-CoV-2 variant through Europe in the summer of 2020
- (2021) Emma B. Hodcroft et al. NATURE
- Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
- (2021) Dan H. Barouch et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
- (2021) Matthew McCallum et al. SCIENCE
- Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
- (2021) Kizzmekia S. Corbett et al. SCIENCE
- Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
- (2021) David R. Martinez et al. SCIENCE
- Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
- (2021) Allison J. Greaney et al. Science Translational Medicine
- Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
- (2021) Rebecca P. Payne et al. CELL
- Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals
- (2021) Brian Grunau et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection
- (2021) Timothy A. Bates et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
- (2021) Akatsuki Saito et al. NATURE
- Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
- (2021) Delphine Planas et al. NATURE
- Plasma Neutralization of the SARS-CoV-2 Omicron Variant
- (2021) Fabian Schmidt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
- (2021) Matthew McCallum et al. SCIENCE
- Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA
- (2021) Ji Eun Oh et al. Science Immunology
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
- (2020) Michael Letko et al. Nature Microbiology
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
- (2020) Markus Hoffmann et al. MOLECULAR CELL
- Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays
- (2020) Katharine H. D. Crawford et al. Viruses-Basel
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
- (2020) Xiuyuan Ou et al. Nature Communications
- Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2
- (2020) James Brett Case et al. Cell Host & Microbe
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
- (2020) Kizzmekia S. Corbett et al. NATURE
- Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
- (2020) Ching-Lin Hsieh et al. SCIENCE
- Distinct conformational states of SARS-CoV-2 spike protein
- (2020) Yongfei Cai et al. SCIENCE
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
- (2020) Luca Piccoli et al. CELL
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- Correlates of protection against SARS-CoV-2 in rhesus macaques
- (2020) Katherine McMahan et al. NATURE
- Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion
- (2019) Alexandra C. Walls et al. CELL
- Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion
- (2017) Alexandra C. Walls et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A new cell-based assay to evaluate myogenesis in mouse myoblast C2C12 cells
- (2015) Manami Kodaka et al. EXPERIMENTAL CELL RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More